Oscar Health, Inc. (OSCR) Reports Q2 Loss, Misses Revenue Estimates

Oscar Health (OSCR) reported a Q2 2025 loss of $0.89 per share, narrowly beating the Zacks consensus estimate of a $0.90 loss, but a significant reversal from a $0.20 per share profit in the year-ago period. Quarterly revenues reached $2.86 billion, missing consensus estimates by 1.25% despite growing from $2.22 billion year-over-year. The stock has underperformed the S&P 500 year-to-date, and an unfavorable trend in earnings estimate revisions has resulted in a Zacks Rank #4 (Sell), suggesting potential continued underperformance.

Analysis

Oscar Health, Inc. (OSCR) presented a mixed financial picture for its second quarter of 2025, characterized by a significant deterioration in profitability despite strong top-line expansion. The company reported a quarterly loss of $0.89 per share, a stark reversal from the $0.20 per share profit recorded in the same period a year ago. While this loss was marginally better than the consensus estimate of a $0.90 loss, the positive earnings surprise of just 1.11% is minimal. Revenues grew to $2.86 billion from $2.22 billion year-over-year, yet this figure missed analyst expectations by 1.25%. This juxtaposition of robust revenue growth against declining profitability and a revenue miss suggests potential margin pressure or operational inefficiencies. Compounding these concerns, the stock has underperformed the S&P 500 year-to-date with a 2.8% gain versus the index's 7.1%. Critically, the trend in earnings estimate revisions leading up to the report was unfavorable, culminating in a Zacks Rank #4 (Sell) and signaling expectations of near-term market underperformance.

Key Decisions for Investors

• Given the swing from profit to a significant loss year-over-year and the miss on revenue estimates, investors should exercise caution and re-evaluate their thesis on the company's path to sustainable profitability.
• Closely monitor management's commentary on the upcoming earnings call for specific guidance on margin outlook and cost controls, as this will be a primary catalyst for the stock's direction.
• The Zacks Rank #4 (Sell) indicates a bearish analyst consensus based on negative earnings estimate revisions, suggesting that holding or initiating a long position carries a risk of near-term underperformance relative to the market.